Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, and went public on January 28, 2019. The company is located in Beijing Economic and Technological Development Zone [1] - The main business areas include drug research, development, and production services, with revenue composition as follows: laboratory services 60.43%, CMC (small molecule CDMO) services 21.58%, clinical research services 14.58%, macromolecule and cell and gene therapy services 3.28%, and others 0.12% [1] Stock Performance - On September 18, Kanglong Chemical's stock rose by 5.38%, reaching a price of 37.40 CNY per share, with a trading volume of 1.849 billion CNY and a turnover rate of 3.63%. The total market capitalization is 66.505 billion CNY [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under China Merchants Fund holds a significant position in Kanglong Chemical. The fund, China Merchants National Bio-Medical Index A (161726), reduced its holdings by 772,800 shares in the second quarter, retaining 15.765 million shares, which accounts for 4.22% of the fund's net value, ranking it as the seventh-largest heavy stock [2] - The fund has a total scale of 7.519 billion CNY and has achieved a return of 24.26% year-to-date, ranking 2223 out of 4222 in its category. Over the past year, the return is 45.43%, ranking 2450 out of 3804, while since its inception, it has incurred a loss of 25.67% [2] Fund Management - The fund manager for China Merchants National Bio-Medical Index A is Hou Hao, who has been in the position for 8 years and 30 days, managing assets totaling 55.459 billion CNY, with the best fund return during his tenure being 758.66% and the worst being -58.37% [3] - Co-manager Xu Rongman has been in the role for 4 years and 179 days, overseeing assets of 27.361 billion CNY, with the best return of 67.05% and the worst also at -58.37% during his tenure [3]

Group 1 - The core viewpoint of the news is that Jianfan Bio (300529.SZ) reported a decrease in institutional investor holdings in its A-shares, with a total of 51.87 million shares held by six institutions, representing 6.49% of the total share capital, down by 2.00 percentage points from the previous quarter [1] Group 2 - In the public fund sector, two public funds increased their holdings, including Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with an increase ratio of 0.25% [2] - Two public funds decreased their holdings, namely, Zhaoshang Guozhen Biomedical Index A and Yifangda Growth Enterprise ETF, with a decrease ratio of 0.11% [2] - Six public funds did not disclose their holdings in the current period, including Guangda Baodexin Credit Enhancement Bond A and others [2] Group 3 - Regarding foreign investment, the Hong Kong Central Clearing Limited is noted as an institution that did not disclose its holdings in the current period [3]

Group 1 - Wante Bio (603392.SH) released its 2024 annual report on April 12, 2025, indicating that as of April 11, 2025, 219 institutional investors disclosed holding A-shares of Wante Bio, totaling 778 million shares, which accounts for 61.50% of the total share capital [1] - The top ten institutional investors include companies such as Yangshengtang Co., Ltd., Hong Kong Central Clearing Limited, and various ETFs, with the top ten collectively holding 60.17% of the shares, a decrease of 0.29 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 22 funds increased their holdings compared to the previous period, with a total increase of 0.16%, including funds like Innovation Drug and Tianhong National Medicine ETF [2] - Conversely, 6 public funds reduced their holdings, with a total decrease of 0.11%, including funds such as Huatai-PB CSI 300 ETF and Morgan CSI Innovation Drug Industry ETF [2] - A total of 189 new public funds were disclosed this period, including major ETFs like E Fund CSI 300 Medicine ETF and Huaxia CSI 300 ETF [2]

Group 1 - The core viewpoint of the news is that as of March 27, 2025, institutional investors hold a significant portion of Tiger Medical's A-shares, totaling 1.76 billion shares, which accounts for 20.31% of the company's total equity [1] - The top ten institutional investors collectively hold 14.86% of Tiger Medical's shares, with a decrease of 1.43 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, while five funds decreased their holdings, with a total reduction rate of 0.19% [2] - A total of 16 new public funds were disclosed this period, including notable funds such as E Fund CSI 300 Medical ETF and others [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.30% compared to the previous quarter [2]